Related Experiment Video

Updated: Jul 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Specific genetic characteristics in patients with familial moyamoya disease

Hidetoshi Ikeda1, Takashi Yoshimoto

  • 1Division of Neurosurgery, Tohoku Graduate School of Medicine, Miyagi, Japan.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|October 2, 2007
PubMed

Insights

Screening for familial moyamoya disease in Japan is crucial for early intervention. This study found a distinct genetic background in Japanese familial moyamoya disease patients, suggesting potential for targeted genetic screening.

Area of Science:

  • Genetics
  • Neurology
  • Mitochondrial DNA analysis

Background:

  • Moyamoya disease screening is vital in Japan to prevent severe neurological deficits in young patients.
  • Familial moyamoya disease is prevalent in the Mongoloid population, necessitating genetic investigation.
  • Increased incidental detection of moyamoya disease, with over half of cases being familial, highlights the need for better diagnostic tools.

Purpose of the Study:

  • To investigate the specific genetic background of familial moyamoya disease in the Japanese population.
  • To identify potential genetic markers for improved screening and preventive protocols.
  • To understand the genetic relatedness within the familial moyamoya disease cohort in Japan.

Main Methods:

  • Analysis of nucleotide sequences in the noncoding D-loop region of mitochondrial DNA.
  • Comparison of mitochondrial DNA sequences between 43 familial moyamoya disease probands and 46 healthy controls.
  • Statistical analysis using the Mann-Whitney U-test to assess the significance of genetic differences.

Main Results:

  • A significant difference in average pairwise divergence was observed between familial moyamoya disease patients (0.63%) and controls (1.2%).
  • The familial moyamoya disease population exhibits a specific genetic profile distinct from the general Japanese population.
  • A close genetic association was identified among familial moyamoya disease patients in Japan.

Conclusions:

  • The Japanese familial moyamoya disease population possesses a unique genetic background.
  • The findings indicate the feasibility of screening for a specific genetic profile in familial moyamoya disease.
  • This research supports the development of targeted genetic screening strategies for early detection and prevention.

More Related Videos

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes08:56

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

Published on: October 10, 2025

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Genetic Lingo01:11

Genetic Lingo

Overview
Pedigree Analysis01:35

Pedigree Analysis

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...